Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer

Abstract EN

Background.

We performed a randomized phase II study comparing efficacy and toxicity of weekly paclitaxel 80 mg/m2 (Weetax) with three weekly docetaxel 75 mg/m2 (Threetax), both in combination with oral capecitabine 1000 mg/m2 twice daily for 2 weeks followed by a 1-week break.

Patients.

Thirty-seven women with confirmed metastatic breast cancer were randomized.

Results.

Median TTF was 174 (Weetax) versus 147 days (Threetax) (P=0.472).

Median OS was 933 (Weetax) versus 464 days (Threetax) (P=0.191).

Reasons for TTF were PD 8/18 (Weetax), 9/19 (Threetax); and toxicity: 8/18 (Weetax), 8/19 (Threetax).

ORR was 72% (Weetax) versus 26% (Threetax) (P=0.01).

The Threetax-combination resulted in a higher incidence of leuco-/neutropenia compared to Weetax.

Grade II anemia was more pronounced in the Weetax group.

No difference was found in quality of life.

Conclusion.

Taxanes in combination with capecitabine resulted in a high level of toxicity.

Taxanes and capecitabine should be considered given sequentially and not in combination.